Cara Therapeutics, Inc. (NASDAQ:CARA) Sees Significant Decrease in Short Interest

Cara Therapeutics, Inc. (NASDAQ:CARA) saw a significant decrease in short interest in the month of December. As of December 31st, there was short interest totalling 142,600 shares, a decrease of 56.7% from the December 15th total of 329,400 shares. Currently, 3.7% of the company’s shares are sold short. Based on an average daily trading volume, of 136,200 shares, the short-interest ratio is currently 1.0 days.

Institutional Investors Weigh In On Cara Therapeutics

Large investors have recently added to or reduced their stakes in the business. FMR LLC boosted its holdings in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 32,789 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Cara Therapeutics during the 3rd quarter valued at $29,000. Finally, Disciplined Growth Investors Inc. MN boosted its stake in Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Cara Therapeutics in a report on Wednesday, January 8th. They issued a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and five have assigned a hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $27.84.

Cara Therapeutics Stock Down 4.5 %

Cara Therapeutics stock traded down $0.21 during trading hours on Wednesday, reaching $4.46. 45,231 shares of the company’s stock were exchanged, compared to its average volume of 92,748. The firm has a market capitalization of $20.38 million, a PE ratio of -2.55 and a beta of 0.51. The firm’s 50 day simple moving average is $4.15 and its 200 day simple moving average is $3.87. Cara Therapeutics has a twelve month low of $2.71 and a twelve month high of $13.80.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.